Notably, inhibition of TRPM4 has shown promise in mitigating arrhythmias induced by hypoxia-reoxygenation in mice and in offering protection against ischemia-reperfusion injury in rat hearts, underscoring its therapeutic potential in cardiovascular disease management (Simard et al., 2012; Pironet et al., 2019). The gene discussed is TRPM4; the disease is cardiovascular disorder.